{"id":51880,"date":"2022-12-12T22:02:34","date_gmt":"2022-12-12T21:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/"},"modified":"2022-12-12T22:02:34","modified_gmt":"2022-12-12T21:02:34","slug":"metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","title":{"rendered":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting"},"content":{"rendered":"
\n

\nData generated in collaboration with Metafora<\/b>\n<\/p>\n

PARIS, France & NEW ORLEANS, La.–(BUSINESS WIRE)–METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed \/ refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugen\u2019s drug candidate WU-NK-01, a novel, off-the-shelf therapy for AML, which Wugen expects to advance to the clinic.<\/b>\n<\/p>\n

<\/a><\/p>\n

\nVincent Petit, CEO of Metafora, said, \u201cWe congratulate our Wugen colleagues on the promising results presented today and are delighted to have contributed to this study by leveraging our platform to decipher cell metabolism. Our platform played an important role in assessing WU-NK-101\u2019s metabolic fitness\u2014a key function of its unique anti-tumor properties. .\u201d\n<\/p>\n

\nCombined with proprietary reagents, our platform can measure metabolic fitness, thus improving the efficacy and safety of cell therapies and reducing manufacturing costs. The analysis platform, METAflow, is a software with unmatched robustness and a seamless, comprehensive, user-friendly interface. In a nutshell, METAflow provides objective, reproducible, traceable results, all in a collaborative digital platform.\n<\/p>\n

\nAbout Metafora<\/b>\n<\/p>\n

\nMETAFORA biosystems\u2019 proprietary reagents and state-of-the-art algorithms allow the detection of “metabolic reprogramming” induced during many disease processes. Evaluating and detecting anomalies in their energy needs, the company\u2019s innovative technology assesses the nutrient requirements of cells simply, rapidly and reproducibly. Metafora\u2019s AI software and reagents thus potentially allow to increase the clinical efficacy and safety of cell therapies and reduce manufacturing costs.\n<\/p>\n

\nIn 2023, METAflow will be rolled out across academia and industry to equip flow cytometrists with a robust and intuitive interface for data interpretation. In parallel, the company is preparing the European launch of METAglut1, for the early diagnosis of De Vivo disease, a rare pediatric neurometabolic disorder for which early diagnosis can be transformative. A number of pipeline programs are to reach clinical stage across other diagnostic areas and cell therapy optimization in the coming 18 months.\n<\/p>\n

\nwww.metafora-biosystems.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information, please contact:<\/b>
Vincent Petit, CEO
\n
Phone: +33 6 76 71 61 14
\n
Email: vincent.petit@metafora-biosystems.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Data generated in collaboration with Metafora PARIS, France & NEW ORLEANS, La.–(BUSINESS WIRE)–METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed \/ refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugen\u2019s drug candidate WU-NK-01, a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51880","6":"format-standard","7":"category-industry"},"yoast_head":"\nMETAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Data generated in collaboration with Metafora PARIS, France & NEW ORLEANS, La.–(BUSINESS WIRE)–METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed \/ refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugen\u2019s drug candidate WU-NK-01, a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T21:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \\\/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting\",\"datePublished\":\"2022-12-12T21:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/\"},\"wordCount\":366,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005691\\\/en\\\/1662180\\\/21\\\/logo_Metafora_RVB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/\",\"name\":\"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \\\/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005691\\\/en\\\/1662180\\\/21\\\/logo_Metafora_RVB.jpg\",\"datePublished\":\"2022-12-12T21:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005691\\\/en\\\/1662180\\\/21\\\/logo_Metafora_RVB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005691\\\/en\\\/1662180\\\/21\\\/logo_Metafora_RVB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \\\/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend","og_description":"Data generated in collaboration with Metafora PARIS, France & NEW ORLEANS, La.–(BUSINESS WIRE)–METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed \/ refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugen\u2019s drug candidate WU-NK-01, a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-12T21:02:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting","datePublished":"2022-12-12T21:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/"},"wordCount":366,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/","name":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg","datePublished":"2022-12-12T21:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221212005691\/en\/1662180\/21\/logo_Metafora_RVB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/metafora-partner-wugen-to-present-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed \/ Refractory AML at the American Society of Hematology\u2019s (ASH) 64th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51880"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51880\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}